Expanded Studies of Risk Factors for Pulmonary-, Liver-, and Cardiovascular Disease in the SCAPIS 2 Stockholm Reexamination

What this Trial Is About

Researchers are conducting the Swedish CArdioPulmonary bioImage Study (SCAPIS), a large national study involving 30,000 randomly selected adults aged 50 to 64, recruited between 2014 and 2018 across six university hospitals in Sweden. The follow-up study, SCAPIS 2, re-examines half of the original participants, with 2,500 individuals in Stockholm undergoing detailed reassessments to study risk factors for lung, liver, and cardiovascular diseases. The SCAPIS 2 study includes core exams like blood sampling, questionnaires, and imaging. Additional specialized assessments in Stockholm involve collecting saliva and blood samples for immune and inflammatory marker analysis, extended questionnaires on breathing, sleep, infections, and dental health, as well as advanced imaging and physiological tests. These tests include cardiac ultrasound, aortic measurements, liver elastography, vascular stiffness measurement by pulse wave analysis and photoplethysmography, and CT scans to assess valve and vessel calcification. Participants will attend study visits for these assessments, including a separate visit lasting about an hour for extended imaging and physiological measurements. Researchers will analyze samples and data to better understand immune activation, lipid profiles, oral microbiota, and their links to heart, lung, and liver diseases. Outcomes include detection of coronary artery disease, liver conditions, aortic aneurysm, and cardiac dysfunction. The study involves long-term follow-up with measurements and imaging repeated to assess disease progression and risk factors.

Expanded Studies on the SCAPIS Stockholm Reexamination Cohort